Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
A wide variety of cutaneous T-cell lymphoma therapies are now used in clinical practice. Treatment options include phototherapy, radiation, topical therapy, systemic mono-chemotherapy, combination chemotherapy, and combined modalities. Many patients fail or develop resistance to monotherapy, resulting in a need for combined treatment modalities to improve therapeutic results in terms of quality of life and duration of response. Recently, bexarotene, a selective antagonist of the retinoid X receptor, has been approved in the treatment of patients with cutaneous T-cell lymphoma. Bexarotene offers new opportunities for combination treatment strategies because of its novel and unique mechanism of action. In this article we review the rationale and examine key published evidence on combining these new treatment modalities.
Guitart
Joan
J
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. jguitart@northwestern.edu
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D004359:Drug Therapy, Combination; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D011701:PUVA Therapy; D012878:Skin Neoplasms / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene